Feasibility of a Deep Learning-based Algorithm for Non-invasive Assessment of Vulnerable Coronary Plaque

Launched by GE HEALTHCARE · Dec 15, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new computer-based technology that helps doctors evaluate the safety of heart artery blockages, also known as coronary plaques. The goal is to see how accurately this technology can identify these plaques and determine how risky they are for patients with conditions like chronic coronary syndrome, stable angina, or acute coronary syndrome. By using this technology, doctors hope to improve the way they assess heart health without needing to perform invasive procedures.

To participate in the trial, patients need to be referred for specific heart imaging tests and meet certain requirements, such as having a diagnosis of chronic coronary syndrome or related heart conditions. However, there are some reasons a person might not be eligible, like having a high body mass index or certain heart conditions. While the trial is not currently recruiting, once it begins, participants will likely undergo imaging tests and be monitored to help researchers understand the effectiveness of this new technology. This study is important because it could lead to better, less invasive ways to assess heart health in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients referred for a clinically indicated CCTA and ICA with OCT imaging examinations;
• • 2. Diagnosis of chronic coronary syndrome, known CAD, or stable angina; AND,
• • 3. Patients with ACS that may undergo a CCTA and not refer directly to the Cath lab for revascularization procedures.
• Exclusion Criteria:
• • 1. Contradictions to contrast;
• • 2. Contraindications for beta blocker;
• • 3. BMI \>30;
• • 4. High heart rate ≥75 BPM;
• • 5. Atrial Fibrillation;
• • 6. Arrythmia or irregular heartbeats;
• • 7. Any prior coronary revascularization;
• • 8. Presence of pacemaker or implantable cardioverter defibrillator; OR,
• • 9. Patients with TAVI/TAVR.